Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent
Open accessThe DOI matches its Crossref record.
Abstract
Research interests on radiosensitive property of gold nanoparticles (GNPs) are rapidly raised because of the extensively proved in vitro effectiveness and clinical necessity. However, the issue of targeted accumulation of GNPs in tumor tissues hindered the transference to in vivo applications. In this study, hybrid nano-sized cyclic Arg-Gly-Asp-conjugated GNPs (cRGD-GNPs) integrated with radioactive iodine-125 was fabricated as tumor-targeted radiosensitizer. Therapeutic effects, including acute apoptosis (2 days post treatment) and long-term influence (up to 21 days), were investigated on NCI-H446 tumor-bearing mice via Tc-99 m-Annexin V SPECT and volume measurements, respectively. Apoptosis and volume loss were consistent in showing that tumor growth was effectively suppressed via the treatment of (125)I-cRGD-GNP sensitized radiotherapy (RT), a more significantly radiosensitive effect than the treatment of non-targeted GNPs with RT, RT treatment alone, and no treatment. SPECT/CT images showed that the uptake of cRGD-GNPs by tumor tissues reached the peak target/non-target value of 4.76 at around 2 h post injection, and dynamic radioactivity monitoring showed that (125)I-cRGD-GNPs maintained about 2.5% of injected dosage at 55 h post injection. For long-term influence, a significant radiosensitized RT-induced volume loss was observed. Hence, cyclic RGD conjugation makes the GNP-based radiosensitizer tumor targeting, offering a new modality for enhancing radiotherapeutic efficacy. Additionally, the introduction of I-125 serves as both a therapeutic factor and a radiotracer for in vivo tracking of GNPs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wang, H., Mu, X., He, H., & Zhang, X.-D. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.003 · Cited by 572
Bilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
Zhao, N., Yang, Z., Li, B., Meng, J., Shi, Z., Li, P., & Fu, S. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s104034 · Cited by 51
“We focused on the radiosensitizing effects of gold nanorods (GNRs) because they are small, easy to synthesize, and endowed with a high absorption cross-section.(24,25) To improve the biocompatibility and stability of GNRs, we used mesoporous silica to encapsulate GNRs (GNRs@mSiO 2 ) and then modified the surface with…”
Evaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapy
Karabuga, M., Erdogan, S., Filikci, K., Hazıroglu, R., Tuncel, M., & Cengiz, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104586 · Cited by 6
Metadata
- Authors
- Su, N., Dang, Y., Liang, G., & Liu, G.
- Venue
- Nanoscale Research Letters
- Published
- 2015-04-02
- Volume
- 10
- Issue
- 1
- Pages
- 160-160
- ISSN
- 1556-276X (ISSN-L)
- 1931-7573
- OpenAlex
- W2122359359
- Cited by
- 66
- References
- 0
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent. https://app.cochat.ai/papers/10.1186/s11671-015-0864-9
- The paper
- Su, N., Dang, Y., Liang, G., & Liu, G. (2015). Iodine-125-labeled cRGD-gold nanoparticles as tumor-targeted radiosensitizer and imaging agent. Nanoscale Research Letters. https://doi.org/10.1186/s11671-015-0864-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.